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Supplementary Information 
Supplementary Materials and Methods: 
siRNA nanoparticle formulation: Nanoparticles were formed in 5 % (w/v) glucose in deionized water 
(D5W) at a charge ratio of 3 +/- and a siRNA concentration of 2 mg/ml unless otherwise indicated. Some 
experiments presented here (NTA, TEM, PET, stability assays) were performed with particles formulated 
with less than 1mol percent AD-PEG modified with a terminal transferrin targeting ligand. No discernible 
differences in size, charge, pharmacokinetics, and behavior at the kidney have been observed between 
particles formulated with or without AD-PEG-Tf(1, 2). 21 base pair unmodified and Cy3 labeled siRNA 
was purchased from Qiagen.  
 
Nanoparticle tracking analysis (NTA): All measurements were performed at room temperature. The 
software used for capturing and analyzing the data was NTA 2.0. For measurements the samples were 
measured for 30 s with manual shutter and gain adjustments. Three measurements of the same sample, 
advancing the sample 20-50ul between measurements, were collected. The error bars displayed on the 
NTA graphs were the standard deviation of the three measurements. 
 
Nanoparticle stability assays: Formulated siRNA nanoparticles were incubated with the indicated 
amount of mouse plasma (collected from Balb/c mice) and/or heparan sulfate isolated from bovine kidney 
(Sigma) for 15 minutes at 37°C. 1µg of each sample was loaded into each well of a 1% (w/v) agarose gel 
and voltage was applied for 20-30 minutes. Visualization was achieved via ethidium bromide staining 
(Sigma).  
 
Animal Studies: All animals were treated according to the NIH Guidelines for Animal Care and Use as 
approved by the Caltech Institutional Animal Care and Use Committee. Mice received i.v. doses of 10 
mg/kg siRNA nanoparticles in D5W. Mice were euthanized by CO2 overdose for organ collection at 
indicated time points. All organs were fixed in 4 % (w/v) paraformaldehyde (PFA) in PBS for 3 days. For 
confocal imaging, nanoparticle formulations contain 80 mole percent Cy3-siGL3.  
 
In vivo siRNA/CDP assembly/disassembly assays:  Samples were collected using Microvette CB 300 
Capillary Blood Collection Tube with EDTA (Sarstedt). Samples were centrifuged for 15 minutes at 
1,300xg and the plasma supernatant loaded onto a 1% agarose gel for analysis. All samples were 
processed within a 1 hour of collection. 
 
Cryo-electron microscopy: Samples were vitrified using an automated climate-controlled plunge-freezer 
(Vitrobot, FEI). Briefly, glow discharged Quantifoil holey carbon grids (SPI Supplies) were loaded into 
the chamber of the Vitrobot and 5ul of samples were applied. Grids were blotted for 1s and drained for 1s 
before being plunged into the center of a Vitrobot cup filled with liquid ethane, they were then quickly 
transferred into the outer ring of the cup containing liquid nitrogen. The grids were stored under liquid 
nitrogen for later analysis.  Samples were visualized in Techni T12 Cryo-electron microscope (FEI) 
equipped with a cryo-specimen holder. Acceleration voltage was set at 120kV. 
 
Transmission electron microcopy: Tissue blocks (~1 mm
3
) were fixed in 2.5 % glutaraldehyde (in 0.1 
M sodium cacodylate, pH = 7.4) for 2 h, stained by 1 % OsO4 at 4 °C for 2 h, and 0.9 % OsO4 and 0.3 % 
K4Fe(CN)6 at 4 °C for 2 h. Gradual dehydration with ethanol and propylene oxide enabled tissue 
embedding in Epon 812 resins (Electron Microscopy Sciences). 80 nm thick sections were deposited on 
carbon and formvar-coated, 200-mesh, nickel grids (EMS) and stained with 3 % (w/v) uranyl acetate and 
Reynolds lead citrate for visualization under a 300 kV TF30UT transmission electron microscope (FEI). 
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Confocal microscopy: Formalin-fixed organs were dehydrated and embedded in molten paraffin to 
generate sections of 4-μm in thickness. Sections were deparrafinized with xylene, rehydrated, and 
mounted with ProLong Gold antifade reagent (Invitrogen) for viewing. The excitation wavelengths of 
Cy3-siRNAs was 543 nm (HeNe laser) and the corresponding emission filter was 560-610 nm. The 
measured resolution at which images were acquired is 512×512 pixels, and the image bit-depth is 8-bit. 
10 sections from each organ were inspected. Typically, 5 glomeruli from each tissue section were 
inspected. The Zeiss LSM Image Browser Software allows the extraction of images.  
 
Micro-PET/CT Imaging:  A micro-PET FOCUS 220 PET scanner and a MicroCAT II CT scanner 
(Siemens) were used for data acquisition.  Mice were anesthetized by using 1.5–2% (v/v) isoflurane. 
siRNA labeled with 
64
Cu (100–300 µCi) (1 Ci =37 GBq)  was injected via tail vein and a dynamic PET 
scan was acquired for 1 h. Total siRNA dose was 2.5mg/kg. The image resolution was 1.7 mm. A 7 
minute micro-CT scan was then performed. AMIDE software (3) was used to examine the 
64
Cu signal 
intensity. Ellipsoid regions of interest were placed to over organs of interest. To ensure accurate 
anatomical positioning, regions of interest were placed on fused micro-PET/CT images generated by the 
AMIDE software.  Values were normalized to an elliptic cylinder region of interest drawn over the entire 
mouse.  
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Supplemental Figure S1: Plasmid DNA will dissociate siRNA from nanoparticles. siRNA nanoparticles 
were formulated and then increasing concentrations of ~6kb plasmid DNA were added. Samples were 
immediately loaded onto the gel.  
 
 
Supplemental Figure S2: Characterization of siRNA nanoparticle components excreted into urine. a,b) 
Images of urine samples taken at multiple time points after injections of either free Cy3-labled siRNA or 
Cy3-labled siRNA nanoparticles. Urine was collected from urinary meatus when released at time of 
euthanasia. c) Gel mobility shift assay on urine samples from mice receiving either free siRNA or siRNA 
nanoparticles. Most of the siRNA remaining exists in complex with CDP in the urine. d) Cy3 label is not 
cleaved off siRNA after 30 minute incubation with 95% plasma at 37°C. No staining agent used in this 
gel, signal results from Cy3 fluorescence. 
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Supplemental Figure S3: (a,b) siRNA nanoparticles are also identified within endothelial cells lining the 
peritubule capillaries10 min after administration of siRNA nanoparticles but not (c) free siRNA. 
E=Endothelial cell, NP=nanoparticle, P=podoyctes, PC=peritubule capillary, R=Erythrocyte, T=Tubule. 
Image sizing was performed with ImageJ software.   
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Supplemental Text 
 
Compartment model of kidney transit of free siRNA and siRNA nanoparticles   
 
Because non-invasive, real-time monitoring of siRNA nanoparticle behavior at the microscopic 
level was not possible, we developed a compartment model of kidney transit to better understand the 
relationships between our microscopic observations and the bulk kidney signal obtained from the PET 
study. Specifically, compartment modeling of the kidney was used to demonstrate how GBM 
accumulation and disassembly of siRNA nanoparticles could result in the dynamics observed in our PET 
study. The goal of the model was to reproduce three key characteristics of the PET data: 
1. Delayed and augmented peak kidney accumulation for siRNA nanoparticles versus siRNA alone 
2. Delayed bladder accumulation for the siRNA nanoparticles versus siRNA alone 
3. Increased total kidney retention of the siRNA nanoparticles versus siRNA alone 
Two models were developed, a free siRNA model and a siRNA nanoparticle model. The free siRNA 
model replicates the behavior of free siRNA in the kidney. Key reaction parameters that describe the rates 
and processes of free siRNA filtration used in the free siRNA model were determined by inserting 
anatomical constraints as well as fitting the free siRNA model predictions to the free siRNA PET data.  
The siRNA nanoparticle model reproduces the behavior of siRNA nanoparticles in the kidney. Two 
additional expressions were included to the siRNA nanoparticle model: (1) deposition and complete 
disassembly of siRNA nanoparticles to free siRNAs at the GBM, and (2) uptake of siRNA nanoparticles 
by peri-tubular capillary endothelial cells. Reaction parameters specific to both expressions were fit to the 
PET data from the siRNA nanoparticles, by holding constant all reaction parameters previously deduced 
from the free siRNA model (see table below).    
 
Part I: Estimation of anatomical parameters 
 
Total renal corpuscle volume (Vrc ): Mice have ~10,000 renal corpuscles per kidney (1). We assumed that 
each renal corpuscle is a sphere of radius 40 µm (2).  
 
Vrc = (4/3) π (40 µm)
 3
 × (2×10
4
 corpuscles) = 0.005 cm
3 
 
Total GBM surface area (Sgbm) and GBM volume (Vgbm): The surface area of GBM in a healthy mouse is 
~2.84 × 10
4
 µm
2
 per renal corpuscle, or equivalently, 5.7 cm
2
 (Sgbm) per mouse (3). We assume a GBM 
thickness of 300nm (5). 
Vgbm = 5.7 cm
2 
× 3×10
-5
cm=1.7×10
-4
cm
3
. 
 
Total kidney interstitial volume (Vint): The cortex, medulla, and pelvis account for 70%, 27%, and 3% of 
the total kidney volume (4). Here, we combined volume contribution from the pelvis and medulla. The 
interstitial fraction in the cortex and medulla amounts to 7% and up to 20%, respectively (5).Vint amounts 
to ~10% of the total kidney volume.  
 
Total renal tubules volume (Vrt): All remaining parts of the kidney other than renal corpuscles and 
interstitial space belong to renal tubules throughout the cortex and medulla.  
 
Vrt = Vkidney - Vrc - Vint = 0.22 cm
3
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Part II: Free siRNA model 
 
Diagram of the compartmental model for free siRNAs in the kidney. GBM = glomerular basement 
membrane, PTC = proximal tubule cells, dotted line: fenestrated walls of glomerular capillaries. 
Blood concentration of siRNA: In order to limit the number of parameters in the model, we chose to 
represent the level of siRNA in blood by a simple exponential decay function.  
 
 tACC NPplasma
siRNA
plasma  exp , where A = 35% ID/cm
3
 and α = 0.6 min-1. 
Values for A and α were derived by curve fitting the PET data for free siRNA. 
Renal filtration of free siRNA: Upon their entry into the glomerular capillary tuft, free siRNAs (MW: c.a. 
13 kDa; size: 3.2 nm) pass through the fenestrated endothelium and permeate into the renal filtration 
barrier (with an apparent permeability Pgbm). Once within the filtration barrier, free siRNAs enter the 
urinary space within the renal tubules at a rate kfilter.  
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In the urinary space, free siRNAs can experience uptake by proximal convoluted tubules (PCTs) (6). This 
model includes an additional rate constant krt that depicts the reabsorption of free siRNAs into PCTs. It 
assumes no reabsorption in other renal tubule components but PCTs. fcortex (= 0.7) and fpct (= 0.64) denote 
the volume fraction of the cortex in the bulk kidney and the fraction of PCTs in the cortex, respectively 
(5).  
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Ultimately, unabsorbed siRNAs depart from the kidney and enter the bladder at a rate kbladder.  
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Part III: siRNA Nanoparticle model  
 
Diagram of the compartmental model for siRNA nanoparticles in the kidney. GBM = glomerular basement 
membrane, PTC = proximal tubule cells, PTEC = peri-tubule endothelial cells, dotted line: fenestrated 
walls of glomerular capillaries.  
Blood concentration of siRNA nanoparticle: same as free siRNA model 
Peri-tubule endothelial cell uptake: Our imaging studies revealed that some siRNA nanoparticles are 
internalized by peri-tubule endothelial cells within the kidney. This region of nanoparticle accumulation is 
likely responsible for the majority of the persistent PET signal observed in the kidney at 30 minutes. 
Because these endothelial cells reside within the interstitial space of the kidney, we used Vint to represent 
the volume of this compartment and deduce the value of 
NP
enk .  
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Renal filtration of siRNA nanoparticles: Our imaging studies revealed that siRNA nanoparticles 
accumulated and are disassembled in the GBM. We model the GBM as a collection of binding sites of 
heparan sulfate ([HS]0).  Each nanoparticle can bind to a site with an equilibrium binding constant
NP
adsK . 
Upon binding and formation of an intermediate complex NP-HS, the degradation of the nanoparticle will 
occur. Compared to binding, degradation is the rate-limiting step (with rate
NPkdeg ). 
HSsiRNAHSNPHSNP
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a d s
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The rate expression describing these processes is as follows:  
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The pores of the glomerular endothelium are ~100 nm in diameter. We believe that the net 
movement of siRNA across this membrane is the same for both free siRNA and siRNA in nanoparticles. 
Because both formulations of siRNA (free or nanoparticle associated) have similar blood clearance rates, 
the net rate for siRNA crossing the glomerulular endothelium for both these formulations are necessarily 
similar. This assertion is further supported by the observations that both siRNA formulations deposit 
similarly in all other sites in the body besides the kidney.  
Physically, the idea of similar rate of endothelial crossing for both siRNA formulations is 
reasonable. While free siRNA experiences less hydrodynamic drag than nanoparticles when crossing the 
glomerular endothelium, they face electrostatic repulsion by the GBM, whereas the positively charged 
siRNA nanoparticles do not. Additionally, each nanoparticle has been estimate to contain ~2000 siRNA 
molecules. Therefore, even if the permeability of the glomeruluar endothelium for an intact nanoparticle 
is less than that of free siRNA, the net rate of siRNA crossing this barrier in nanoparticle form could be 
equivalent. Therefore, we set Pgbm of the nanoparticle to be the same as the Pgbm determined in curve 
fitting of the preliminary model for free siRNA.  
 
The governing equations of siRNA nanoparticle accumulation and disassembly in the GBM are: 
Nanoparticle accumulation and disassembly: 
NP
gbm
NP
ads
NP
gbm
NP
ads
NP
gbm
NP
gbm
NP
plasmagbm
NP
gbm
NP
gbm
CK
CKHSk
V
CCSP
dt
dC




1
][)( 0deg
 
Released free siRNA in GBM: 
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Total GBM heparan sulfate concentration ([HS]0): Based on the PET experiment, each mouse (20 g) 
receives infusion of siRNA (in free or nanoparticle form) at an amount of 2.5 mg/kg. This means each 
whole dose (100% ID) contains 50 µg of siRNA. This translates to ~9 × 10
16
 anionic charges/ID.    
 
(50 µg-siRNA/kidneys) × (mol-siRNA/14000 g-siRNA) × (42 mol-saccharide /mol-siRNA) × (1 mol-
anionic charge/mol-saccharide) × (6.02 ×10
23
 anionic charge/mol-charge) = 9×10
16
 anionic charge/ID. 
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With known amounts of GBM in renal corpuscles and content of heparan sulfate in each corpuscle, we 
can estimate [HS]0 in equivalent terms of the percent injected dose (%ID) (7, 8).  
 
(188 µg-GBM/corpuscle) × (13.3 µg-HS/mg-GBM) × (mol-HS/75000 g-HS) × (220 mol-saccharide /mol-
HS) × (2 mol-anionic charge/mol-saccharide) × (6.02 ×10
23
 anionic charge/mol-charge) × (corpuscle/(4π 
(40 µm)
3
/3)) × (100% ID/9×10
16
 anionic charge) = 4×10
6
 %ID/cm
3
.  
 
This represents an extremely high and localized concentration of negative charge within the GBM. 
 
The model assumes full degradation of nanoparticles such that the only component filtered out of 
the glomerular basement membrane to the urinary space is free siRNA. We therefore employ the same 
equations for PCT uptake and delivery to bladder as in the free siRNA model. 
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List of parameters  
The governing differential equations (with their initial conditions) were solved with MATLAB using 
ODE15s with the appropriate initial conditions.  
 
Table I: Anatomical parameters 
Name Description (units) Determination Method Value 
Vkidney Total kidney volume (cm
3
)  Direct measurement 0.25 
Vrc Total renal corpuscles volume (cm
3
) Estimated from (1, 2) 5×10
-3
 
Vgbm Total kidney GBM volume (cm
3
) Estimated from Sgbm 1.7×10
-4 
Sgbm Total kidney GBM surface area (cm
2
) Estimated from (3)  5.7
 
Vint Total kidney interstitial volume (cm
3
) Estimated from (4, 5) 0.025
 
Vrt Total renal tubules volume (cm
3
) Estimated from Vkidney 0.22
 
fcortex Volume fraction of cortex Estimated from (5) 0.7  
fpct Volume fraction of proximal convoluted tubules Estimated from (5) 0.64 
[HS]0 Total heparan sulfate concentration (% ID/cm
3
) Estimated from (7, 8) 4×10
6
 
Vblood Total blood volume (cm
3
) Estimated from (9) 1.5 
HCRT Hematocrit Estimated from (9)  33% 
Vbladder Total bladder volume (cm
3
) Estimated from (10)  0.15 
 
Table II: Reaction parameters 
Name Description (units) Source of data for fitting Value 
A  Plasma concentration (% ID/cm
3
) Blood clearance  35 
α Rate of elimination (min-1) Blood clearance 0.6 
Pgbm GBM apparent permeability (cm min
-1
) Kidney  -- free siRNA 10000 
kfilter Rate of filtration into renal tubules/pelvis (min
-1
) Kidney  -- free siRNA 600 
kbladder Rate of filtration into bladder (min
-1
) Kidney  -- free siRNA 0.2 
krt Rate of renal tubule reabsorption (% ID cm
-3 
min
-1
) Kidney  -- free siRNA 2 
Kads Equilibrium binding constant to GBM (% ID cm
-3
)
-1 
Kidney  -- nanoparticle 10 
kdeg Rate of nanoparticle degradation (min
-1
) Kidney  -- nanoparticle 1×10
-3
 
ken Rate of peri-tubule endothelial uptake (min
-1
) Kidney  -- nanoparticle 1.3 
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